Frontiers in Oncology (Oct 2020)
Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor
- Rahul Mal,
- Alexa Magner,
- Joel David,
- Jharna Datta,
- Meghna Vallabhaneni,
- Mahmoud Kassem,
- Mahmoud Kassem,
- Jasmine Manouchehri,
- Natalie Willingham,
- Daniel Stover,
- Daniel Stover,
- Jeffery Vandeusen,
- Jeffery Vandeusen,
- Sagar Sardesai,
- Sagar Sardesai,
- Nicole Williams,
- Nicole Williams,
- Robert Wesolowski,
- Robert Wesolowski,
- Maryam Lustberg,
- Maryam Lustberg,
- Ramesh K. Ganju,
- Bhuvaneswari Ramaswamy,
- Bhuvaneswari Ramaswamy,
- Mathew A. Cherian,
- Mathew A. Cherian
Affiliations
- Rahul Mal
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Alexa Magner
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Joel David
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Jharna Datta
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Meghna Vallabhaneni
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Mahmoud Kassem
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Mahmoud Kassem
- Stefanie Spielman Comprehensive Breast Cancer, The Ohio State University, Columbus, OH, United States
- Jasmine Manouchehri
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Natalie Willingham
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Daniel Stover
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Daniel Stover
- Stefanie Spielman Comprehensive Breast Cancer, The Ohio State University, Columbus, OH, United States
- Jeffery Vandeusen
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Jeffery Vandeusen
- Stefanie Spielman Comprehensive Breast Cancer, The Ohio State University, Columbus, OH, United States
- Sagar Sardesai
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Sagar Sardesai
- Stefanie Spielman Comprehensive Breast Cancer, The Ohio State University, Columbus, OH, United States
- Nicole Williams
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Nicole Williams
- Stefanie Spielman Comprehensive Breast Cancer, The Ohio State University, Columbus, OH, United States
- Robert Wesolowski
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Robert Wesolowski
- Stefanie Spielman Comprehensive Breast Cancer, The Ohio State University, Columbus, OH, United States
- Maryam Lustberg
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Maryam Lustberg
- Stefanie Spielman Comprehensive Breast Cancer, The Ohio State University, Columbus, OH, United States
- Ramesh K. Ganju
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Bhuvaneswari Ramaswamy
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Bhuvaneswari Ramaswamy
- Stefanie Spielman Comprehensive Breast Cancer, The Ohio State University, Columbus, OH, United States
- Mathew A. Cherian
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States
- Mathew A. Cherian
- Stefanie Spielman Comprehensive Breast Cancer, The Ohio State University, Columbus, OH, United States
- DOI
- https://doi.org/10.3389/fonc.2020.587386
- Journal volume & issue
-
Vol. 10
Abstract
Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) belong to a superfamily of nuclear receptors called steroid hormone receptors, which, upon binding ligand, dimerize and translocate to the nucleus where they activate or repress the transcription of a large number of genes, thus modulating critical physiologic processes. ERβ has multiple isoforms that show differing association with prognosis. Expression levels of the full length ERβ1 isoform are often lower in aggressive cancers as compared to normal tissue. High ERβ1 expression is associated with improved overall survival in women with breast cancer. The promise of ERβ activation, as a potential targeted therapy, is based on concurrent activation of multiple tumor suppressor pathways with few side effects compared to chemotherapy. Thus, ERβ is a nuclear receptor with broad-spectrum tumor suppressor activity, which could serve as a potential treatment target in a variety of human cancers including breast cancer. Further development of highly selective agonists that lack ERα agonist activity, will be necessary to fully harness the potential of ERβ.
Keywords
